Abrysvo, Pfizer's respiratory syncytial virus (RSV), has been approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in people 18 to 59 years of age. Our Deputy Director, Dr. Elissa Malkin, led a clinical site that participated in a pivotal phase 3 MONET clinical trail that contributed data to this impactful study. This vaccine is the first RSV vaccine approved for adults younger than 50 years of age and is crucial for at-risk individuals in this age-group.
(image from Getty images)
